Not every news cycle adds clarity. This piece on where will pfizer stock be in 3 years? aims to do exactly that: cut the noise, share the core facts, and offer a balanced read of the implications for individuals and small businesses.
Investors should always consider the long game when looking at stocks. Even if a business is not doing well right now, that doesn’t mean it’ll always be the case. Looking at a broader time frame can help you identify promising long-term buys.
One stock that is an intriguing one to consider is Pfizer (NYSE: PFE). These days, it hasn’t been a hot stock to own, not by any stretch. Investors are worried about its growth. Its recent results haven’t been impressive, and while the dividend offers a high yield, there may be concerns about it as well. The result has been a stock that’s been in deep trouble: in five years, Pfizer’s stock has declined by close to 30%.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Below, I’ll look at where the business might be in the next three years, and whether it’s worth investing in the healthcare stock today.
Over the next few years, Pfizer’s sales from some of its top drugs are likely to decline heavily as the company faces patent cliffs for Eliquis, Ibrance, Xtandi, Xeljanz, and other products. Previously, in 2022, CEO Albert Bourla projected that the company might lose up to $18 billion in revenue from 2025 through to 2030, as a result of competition from generics. But at the same time, Bourla has also been planning to more than offset that with increases to the top line via acquisitions and in-house development. At the time, he said he was planning to bolster the company’s top line by as much as $25 billion.
And in recent years, Pfizer has been busy with acquisitions to reach that goal. Its most high-profile purchase was the company’s $43 billion acquisition of Seagen in 2023, an oncology company that makes advanced cancer treatments. Last year, Pfizer also bought Metsera for up to $10 billion. Metsera is developing GLP-1 drugs, which could potentially make Pfizer a major player in the anti-obesity market.
The big question mark is what Pfizer’s financials might look like when all the dust settles from not just the patent cliffs but also all the wheeling and dealing it’s been doing in recent years, and whether it will come out ahead. There will be declines in revenue from leading products today, but new ones could also fill the void and potentially more than make up for any losses.
